Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: The impact on depression, anxiety and quality of life level

Rheumatology International

Volumn 32, Issue 2, 2012, Pages 323-330

  Ertenli, I ^a   Ozer, S ^a   Kiraz, S ^a   Apras, S B ^a   Akdogan, A ^a   Karadag, O ^a   Calguneri, M ^a   Kalyoncu, U ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Cytokines; Infliximab; Major depressive disorder

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ANXIETY; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857036853     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1616-x     Document Type: Article

References (35)

1. J Braun J Sieper 2007 Ankylosing spondylitis Lancet 369 1379 1390 17448825 10.1016/S0140-6736(07)60635-7 (Pubitemid 46590387)
2. JH Barlow SJ Macey GR Struthers 1993 Gender, depression, and ankylosing spondylitis Arthritis Care Res 6 45 51 8443258 10.1002/art.1790060109 1:STN:280:DyaK3s7osVSisA%3D%3D (Pubitemid 23108570)
3. J Martindale J Smith CJ Sutton D Grennan L Goodacre JA Goodacre 2006 Disease and psychological status in ankylosing spondylitis Rheumatology 45 1288 1293 16595514 10.1093/rheumatology/kel115 1:STN:280:DC%2BD28rmvFWktQ%3D%3D (Pubitemid 44542072)
4. A Zink J Braun J Listing J Wollenhaupt 2000 Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database J Rheumatol 27 613 622 10743798 1:STN:280: DC%2BD3c3gsFKguw%3D%3D (Pubitemid 30151336)
5. Evans DL, Charney DS, Lewis L et al (2005) Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58:175-189 (Pubitemid 41112265)
6. CL Raison L Capuron AH Miller 2006 Cytokines sing the blues: inflammation and the pathogenesis of depression Trends Immunol 27 24 31 16316783 10.1016/j.it.2005.11.006 1:CAS:528:DC%2BD28XmsVylsg%3D%3D (Pubitemid 43083561)
7. S Alesci PE Martinez S Kelkar I Ilias DS Ronsaville SJ Listwak AR Ayala J Licinio HK Gold MA Kling GP Chrousos PW Gold 2005 Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications J Clin Endocrinol Metab 90 2522 2530 15705924 10.1210/jc.2004-1667 1:CAS:528:DC%2BD2MXkt1Wgsrk%3D (Pubitemid 40686286)
8. AJ Thomas S Davis C Morris E Jackson R Harrison JT O'Brien 2005 Increase in interleukin-1beta in late-life depression Am J Psychiatry 162 175 177 15625217 10.1176/appi.ajp.162.1.175 (Pubitemid 40095688)
9. C Tuglu SH Kara O Caliyurt E Vardar E Abay 2003 Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder Psychopharmacology 170 429 433 12955291 10.1007/s00213-003-1566-z 1:CAS:528:DC%2BD3sXpt1Chs7w%3D (Pubitemid 38010515)
10. S Lanquillon JC Krieg U Bening-Abu-Shach H Vedder 2000 Cytokine production and treatment response in major depressive disorder Neuropsychopharmacology 22 370 379 10700656 10.1016/S0893-133X(99)00134-7 1:CAS:528:DC%2BD3cXhsVajsbo%3D (Pubitemid 30105765)
11. Kubera M, Maes M, (2000) Serotonin-immune interactions in major depression. In: Patterson, Kordon, Christen (eds) Neuro-immune interactions in neurologic and psychiatric disorders. Springer-Verlag, Berlin, pp 79-87
12. SM O'Brien LV Scott TG Dinan 2004 Cytokines: abnormalities in major depression and implications for pharmacological treatment Hum Psychopharmacol 19 397 403 15303243 10.1002/hup.609 (Pubitemid 39172804)
13. P Persoons S Vermeire K Demyttenaere B Fischler J Vandenberghe LV Oudenhove, et al. 2005 The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab Aliment Pharmacol Ther 22 101 110 16011668 10.1111/j.1365-2036.2005.02535.x 1:CAS:528:DC%2BD2MXpt1Cjt7s%3D (Pubitemid 41039698)
14. GR Lichtenstein M Bala C Han K DeWoody T Schaible 2002 Infliximab improves quality of life in patients with Crohn's disease Inflamm Bowel Dis 8 237 243 12131606 10.1097/00054725-200207000-00001 (Pubitemid 34784975)
15. IM Minderhoud M Samsom B Oldenburg 2007 Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 13 2089 2093 17465453 1:CAS:528:DC%2BD2sXmsFOnsrk%3D (Pubitemid 46795847)
16. S Tyring A Gottlieb K Papp K Gordon C Leonardi A Wang, et al. 2006 Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial Lancet 367 29 35 16399150 10.1016/S0140-6736(05)67763-X 1:CAS:528:DC%2BD28XhsFamuw%3D%3D (Pubitemid 43038667)
17. S Van der Linden HA Valkenburg A Cats 1984 Evaluation of diagnostic criteria for ankylosing spondylitis Arthritis Rheum 27 361 367 6231933 10.1002/art.1780270401
18. J Braun T Pham J Sieper, et al. 2003 International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis 62 817 824 12922952 10.1136/ard.62.9.817 1:CAS:528:DC%2BD3sXns1SisLg%3D (Pubitemid 37026490)
19. Y Akkoc AG Karatepe S Akar Y Kirazli N Akkoc 2005 A Turkish version of the Bath Ankylosing Spondylitis disease activity index: reliability and validity Rheumatol Int 25 280 284 14730386 10.1007/s00296-003-0432-y (Pubitemid 40767833)
20. AS Zigmond RP Snaith 1983 The hospital anxiety and depression scale Acta Psychiatr Scand 67 361 370 6880820 10.1111/j.1600-0447.1983.tb09716.x 1:STN:280:DyaL3s3nvFWjug%3D%3D (Pubitemid 13098606)
21. Ö Aydemir T Güvenir L Küey S Kültür 1997 The reliability and validity of Turkish form of Hospital Anxiety and Depression Scale Turk psikiyatri Derg 8 280 287 (in Turkish)
22. AT Beck RA Steer MG Garbin 1988 Psychometric properties of the Beck depression inventory: twenty-five years of evaluation Clin Psychol Rev 8 77 100 10.1016/0272-7358(88)90050-5 (Pubitemid 18045797)
23. N Hisli 1989 Beck depression envanterinin üniversite öǧrencileri için geçerliliǧi, güvenilirliǧi. A reliability and validity study of Beck Depression Inventory in a university student sample J Psychol (Psikoloji Dergisi) 7 3 13 (in Turkish)
24. Koçyiǧit H, Aydemir Ö, Ölmez N, Memiş A (1999) The reliability and validity of SF-36 for Turkish language. Ege Fizik Tedavi ve Rehabilitasyon Dergisi 12:102-106 (in Turkish)
25. Walker EA, Gelfand MD, Gelfand AN et al (1996) The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry 18:220-229 (Pubitemid 26251507)
26. Katon WJ, Ciechanowski P (2002) Impact of major depression on chronic medical illness. J Psychosom Res 53:859-863 (Pubitemid 35282614)
27. Ware JE (1995) The status of health assessment 1994. Annu Rev Public Health 16:327-354
28. Beusterien KM, Steinwald B, Ware JE (1996) Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly. J Geriatr Psychiatry Neurol 9:13-21 (Pubitemid 26090771)
29. Coulehan JL, Schulberg HC, Block MR et al (1997) Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Intern Med 157:1113-1120 (Pubitemid 27215434)
30. Yonkers KA, Samson JA (2008) Mood disorders measures. In: Rush AJ, First MB, Blacker D (eds) Handbook of psychiatric measures, 2nd edn. American Psychiatric Publishing, Arlington VA, pp 499-528
31. Eren İ, Şahin M, Cüre E et al (2007) Interactions between psychiatric symptoms and disability and quality of life in ankylosing spondylitis patients. Arch Neuropsychiatry 44:1-9
32. Müller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988-1000
33. Myint AM, Kim YK (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypothesis 61:519-525 (Pubitemid 37411894)
34. Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacol 31:2121-2131 (Pubitemid 44413189)
35. Raison C A study of infliximab for treatment resistant major depression emory university. http://clinicaltrials.gov/show/NCT00463580